Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo
Scott, Bart L.
Kishtagari, Ashwin
Sanikommu, Srinivasa R.
Al-Kali, Aref
Lee, Je-Hwan
Burgues, Juan M. Bergua
Diez-Campelo, Maria
Erba, Harry P.
Garcia-Hernandez, Carmen
Santillana, Guillermo Sanz
O'Connell, Casey
Jang, Jun-Ho
Shin, Dong-Yeop
Sayar, Hamid
Rao, Mayank
Schwartz, Richard S.
An, Grace
Jin, Feng
Forgie, Alison J.
Tsiatis, Athanasios C.
Altman, Jessica K.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT060
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [2] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
    Desikan, Sai Prasad Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval
    Yilmaz, Musa
    Konopleva, Marina
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Schneider, Heather
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3704 - +
  • [3] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Tiu, Ramon V.
    Komrokji, Rami
    Lancet, Jeffrey
    Advani, Anjali S.
    Afable, Manuel
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Tabarroki, Ali
    Visconte, Valeria
    Makishima, Hideki
    Jerez, Andres
    Paquette, Ronald
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2012, 120 (25) : 4945 - 4951
  • [4] Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Cortes, Jorge E.
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval G.
    Jain, Nitin
    Naqvi, Kiran
    Jabbour, Elias J.
    Sheppard, Kimberly B.
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2018, 132
  • [5] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Tiu, Ramon V.
    Advani, Anjali S.
    Afable, Manual
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Paquette, Ronald
    Smith, April
    Strozniak, Lori
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [6] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
    Chien, Kelly S.
    Kim, Kunhwa
    Nogueras-Gonzalez, Graciela M.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Huang, Xuelin
    Sheppard, Kimberly B.
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 378 - 387
  • [7] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Ganetsky, Rebecca
    Latham, Deborah
    Paulic, Katarina
    Afable, Manuel
    Saba, Hussain I.
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
  • [8] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
    Chen, James Yuhtyng
    Johnson, Lisa
    McKenna, Kelly Marie
    Choi, Timothy S.
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan M.
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris H. M.
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [10] Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Borthakur, Gautam
    Konopleva, Marina
    Ravandi, Farhad
    Wierda, William G.
    Estrov, Zeev
    Faderl, Stefan
    Kadia, Tapan
    Rey, Kristy
    Cheung, Cora
    Kantajian, Hagop M.
    BLOOD, 2011, 118 (21) : 1122 - 1122
12345